• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

弥漫性非霍奇金淋巴瘤治疗后发生结节性淋巴瘤的晚期复发。

Late relapse with nodular lymphoma after treatment for diffuse non-Hodgkin's lymphoma.

作者信息

Marazuela M, Yebra M, Girón J A, Menéndez J L, Vargas J A, España P, Garcia-Font M, Durántez A

机构信息

Service of Internal Medicine I, Clinica Puerta de Hierro Madrid, Spain.

出版信息

Cancer. 1991 Apr 1;67(7):1950-3. doi: 10.1002/1097-0142(19910401)67:7<1950::aid-cncr2820670721>3.0.co;2-d.

DOI:10.1002/1097-0142(19910401)67:7<1950::aid-cncr2820670721>3.0.co;2-d
PMID:2004309
Abstract

Histologic conversion from a low-grade non-Hodgkin's lymphoma (NHL) into a more aggressive histologic pattern is a common, well-documented event in NHL. The converse phenomenon, appearance of a low-grade, follicular NHL after treatment for diffuse, intermediate, or high-grade NHL, has only recently been recognized. The clinical, morphologic, and immunologic features of a patient in whom relapse with an indolent nodular lymphoma was noticed after combination chemotherapy for diffuse lymphoma are presented. Immunologic markers at presentation and relapse were similar. Other previously reported cases are reviewed. Implications for diagnosis and therapy as well as the pathogenesis of this unique form of conversion are discussed.

摘要

从低度非霍奇金淋巴瘤(NHL)组织学转变为侵袭性更强的组织学类型,是NHL中一种常见且有充分文献记载的现象。相反的现象,即在弥漫性、中度或高度NHL治疗后出现低度滤泡性NHL,直到最近才被认识到。本文介绍了一名弥漫性淋巴瘤患者在联合化疗后复发为惰性结节性淋巴瘤的临床、形态学和免疫学特征。初诊和复发时的免疫标志物相似。还回顾了其他先前报道的病例。并讨论了这种独特转变形式对诊断和治疗的意义以及发病机制。

相似文献

1
Late relapse with nodular lymphoma after treatment for diffuse non-Hodgkin's lymphoma.弥漫性非霍奇金淋巴瘤治疗后发生结节性淋巴瘤的晚期复发。
Cancer. 1991 Apr 1;67(7):1950-3. doi: 10.1002/1097-0142(19910401)67:7<1950::aid-cncr2820670721>3.0.co;2-d.
2
Relapse with nodular lymphoma following combination chemotherapy for diffuse non-Hodgkin's lymphoma.弥漫性非霍奇金淋巴瘤联合化疗后出现结节性淋巴瘤复发。
Am J Clin Oncol. 1986 Oct;9(5):420-3. doi: 10.1097/00000421-198610000-00012.
3
High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.高剂量疗法及自体干细胞支持用于化疗敏感型转化型低度滤泡性非霍奇金淋巴瘤:来自欧洲骨髓移植登记处的病例对照研究
J Clin Oncol. 2001 Feb 1;19(3):727-35. doi: 10.1200/JCO.2001.19.3.727.
4
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).苯达莫司汀、长春新碱和泼尼松(BOP)对比环磷酰胺、长春新碱和泼尼松(COP)治疗晚期惰性非霍奇金淋巴瘤和套细胞淋巴瘤:一项随机III期试验(OSHO#19)的结果
J Cancer Res Clin Oncol. 2006 Feb;132(2):105-12. doi: 10.1007/s00432-005-0023-2. Epub 2005 Aug 9.
5
Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.非霍奇金淋巴瘤的骨髓受累:淋巴结与骨髓形态学不一致的临床意义。内布拉斯加淋巴瘤研究组
J Clin Oncol. 1990 Jul;8(7):1163-72. doi: 10.1200/JCO.1990.8.7.1163.
6
The therapeutic use of rituximab in non-Hodgkin's lymphoma.利妥昔单抗在非霍奇金淋巴瘤中的治疗应用。
Eur J Haematol Suppl. 2007 Jan(67):5-14. doi: 10.1111/j.1600-0609.2006.00789.x.
7
Obstructive solitary bronchial non-Hodgkin's lymphoma--a rare presentation of primary extranodal disease.阻塞性孤立性支气管非霍奇金淋巴瘤——原发性结外疾病的一种罕见表现。
Leuk Lymphoma. 1992 Nov;8(4-5):405-7. doi: 10.3109/10428199209051021.
8
[Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].采用ProMACE-CytaBOM方案治疗侵袭性非霍奇金淋巴瘤
Srp Arh Celok Lek. 1998 Sep-Oct;126(9-10):345-8.
9
[Occurrence of follicular small cleaved cell lymphoma following chemotherapy for diffuse large cell lymphoma].
Rinsho Ketsueki. 1994 Jul;35(7):676-81.
10
Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?在恶性疾病的发展过程中,细胞遗传学异常是否先于形态学异常出现?
Eur J Haematol. 2007 Feb;78(2):152-6. doi: 10.1111/j.1600-0609.2006.00798.x.

引用本文的文献

1
Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy.一线接受免疫化疗的Ⅰ-Ⅱ期弥漫性大B细胞淋巴瘤患者的临床特征及复发风险
Clin Med Insights Blood Disord. 2013 Nov 14;6:23-7. doi: 10.4137/CMBD.S12713. eCollection 2013.